Beam Therapeutics has dosed the first patient in the global pivotal cohort evaluating BEAM-302, moving its one-time in vivo base-editing therapy closer to a potential accelerated approval pathway for alpha-1 antitrypsin deficiency. The cohort expands the company’s ongoing Phase 1/2 trial and will assess whether a single 60-milligram dose can produce durable changes in alpha-1 antitrypsin biomarkers over 12 months.
The milestone places BEAM-302 among the most clinically advanced treatments designed to correct the underlying genetic cause of alpha-1 antitrypsin deficiency rather than repeatedly replacing the missing protective protein. Beam Therapeutics is enrolling patients with disease affecting the lungs, with or without accompanying liver disease, and intends for the pivotal cohort to support a possible United States biologics license application.
BEAM-302 uses lipid nanoparticles to deliver base-editing components to liver cells. The therapy is intended to convert the disease-causing PiZ mutation in the SERPINA1 gene into a sequence that produces functional M-type alpha-1 antitrypsin. By correcting a single DNA letter without deliberately cutting both strands of the DNA molecule, the program is designed to increase protective circulating protein while reducing the abnormal protein that accumulates in the liver.
The pivotal cohort turns promising biomarker changes into a potential approval test
Beam Therapeutics plans to enroll approximately 50 additional patients in the expanded open-label Phase 1/2 study. The selected 60-milligram dose will be evaluated using alpha-1 antitrypsin biomarkers measured over 12 months, following regulatory discussions with the United States Food and Drug Administration about a potential accelerated approval route.
Accelerated approval would allow the regulator to consider a biomarker reasonably likely to predict clinical benefit rather than waiting for direct evidence that treatment slows emphysema, prevents liver damage or reduces transplantation. Any approval based on that route would typically require later confirmation that the biomarker improvement translates into meaningful patient benefit.
The pivotal design is therefore built around the biological consequences of successful gene correction. Investigators will need to show that patients consistently produce enough functional alpha-1 antitrypsin to protect lung tissue, that the corrected protein remains durable and that mutant Z-type protein continues to decline. Safety monitoring will remain particularly important because the editing components are delivered directly into the body and cannot simply be removed after treatment.
The company began pivotal dosing earlier than the broad second-half 2026 timeline it provided in March. Beam Therapeutics said it intends to use its existing international clinical network to enroll the additional patients, although it has not provided a target date for completing recruitment or filing a biologics license application for BEAM-302.
The next clinical update is scheduled for the European Respiratory Society Congress in Barcelona between September 5 and September 9, 2026. The late-breaking presentation is expected to provide updated Phase 1/2 data and could clarify whether the protein changes reported earlier in the year have persisted with longer follow-up.
Earlier BEAM-302 data explain why Beam Therapeutics selected the 60-milligram dose
Beam Therapeutics selected the pivotal dose after treating 29 patients across single-dose and multidose cohorts as of the February 10, 2026 data cutoff. Twenty-eight patients were considered evaluable for measures of biological activity, while safety information from 26 patients who received single doses supported testing at doses as high as 75 milligrams.
Patients who received a single 60-milligram dose reached a mean steady-state total alpha-1 antitrypsin concentration of 16.1 micromolar, with follow-up ranging from five to 12 months. Every patient in that cohort remained above the 11-micromolar threshold that has traditionally been associated with protection against severe lung disease. The 75-milligram group reached a lower mean concentration of 14.4 micromolar, supporting the decision not to advance the higher dose.
The composition of the circulating protein was also important. Corrected M-type alpha-1 antitrypsin accounted for an average of 94% of total protein in the 60-milligram cohort, while mutant Z-type protein declined by an average of 84%. Those results suggested that the treatment was not merely increasing overall protein levels but was shifting production toward the functional form and away from the toxic mutant form.
One patient provided an early indication that the corrected gene continued responding to normal physiological signals. During a respiratory infection around eight months after treatment, the patient’s total alpha-1 antitrypsin concentration increased from 15.9 micromolar to 29.5 micromolar while maintaining a 95% corrected M-type composition. Beam Therapeutics has argued that this inducible response could distinguish gene correction from conventional protein replacement, which does not restore the natural regulation of the SERPINA1 gene.
The single-dose safety findings were generally manageable at the February cutoff, with no serious adverse events or dose-limiting toxicities reported. Observed events included temporary mild or moderate infusion reactions and asymptomatic increases in liver enzymes.
The small multidose group produced a more cautionary result. After a second 60-milligram dose, all three patients experienced moderate infusion reactions, one developed a severe alanine aminotransferase elevation alongside a serious aspartate aminotransferase elevation, and another developed a moderate alanine aminotransferase increase. The liver enzyme elevations were asymptomatic, required no treatment and were not accompanied by increased bilirubin, but the findings reinforced the attraction of achieving sufficient editing with one dose.
Correcting the PiZ mutation could address both sides of alpha-1 antitrypsin deficiency
Severe alpha-1 antitrypsin deficiency is most commonly associated with two copies of the PiZ mutation. The mutation causes the alpha-1 antitrypsin protein to fold incorrectly and accumulate inside liver cells rather than entering circulation in sufficient quantities.
The resulting disease has two interconnected components. Low circulating alpha-1 antitrypsin leaves lung tissue vulnerable to neutrophil elastase, an enzyme released during inflammation that can progressively damage the lungs and contribute to early emphysema. At the same time, the abnormal Z-type protein trapped in the liver can cause inflammation, fibrosis, cirrhosis, liver failure and an increased risk of liver cancer.
Approved augmentation therapies can increase circulating alpha-1 antitrypsin in patients with lung disease, but they require repeated infusions and do not correct the genetic mutation or remove the abnormal protein from the liver. BEAM-302 is intended to address both problems through a single intervention by increasing functional protein and reducing production of the liver-damaging mutant protein.
That dual mechanism is the central reason the pivotal program could become important. A treatment that protects the lungs while also reducing liver toxicity would address a broader disease burden than protein replacement alone. The biomarker-driven accelerated approval strategy, however, means long-term follow-up will still be needed to establish whether molecular correction actually slows clinical deterioration.
The initial study remains open label and includes relatively few patients, so the earlier biomarker results may not fully predict outcomes in the expanded cohort. Investigators must also determine whether editing remains stable over several years, whether immune reactions emerge with broader use and whether unintended genetic changes remain below clinically meaningful levels.
September data and a $1.2 billion cash position shape Beam Therapeutics’ outlook
Beam Therapeutics ended June 2026 with approximately $1.15 billion in cash, cash equivalents and marketable securities. The company expects those resources, together with another $200 million it anticipates drawing from its financing facility with Sixth Street, to support planned operations into the middle of 2029.
That projected runway is expected to finance the BEAM-302 pivotal program, the anticipated launch preparations for sickle cell therapy risto-cel and early clinical work for BEAM-304 in phenylketonuria. The balance sheet gives Beam Therapeutics more room than many clinical-stage biotechnology companies to advance multiple late-stage programs without immediately returning to investors for additional capital.
The company nevertheless recorded a second-quarter net loss of $122.7 million, compared with $102.1 million during the corresponding period of 2025. Research and development expenses totaled $95.1 million, reflecting the cost of running several gene-editing programs and preparing assets for regulatory submissions.
Beam Therapeutics shares rose $2.47 to approximately $28.35 during the August 4 session, a gain of about 9.5%, while the company’s market capitalization approached $2.93 billion. The positive reaction suggests investors welcomed the start of pivotal dosing and the company’s broader clinical progress, although the September data presentation is likely to provide a more detailed test of sentiment. The explanation for the share movement is an inference from the trading pattern rather than a confirmed account from market participants.
The pivotal-cohort milestone moves BEAM-302 from early proof of biological activity toward a study intended to support registration. Earlier data indicate that a single dose can generate functional protein above the historical protective threshold while sharply reducing mutant protein, but the expanded cohort must reproduce those findings across more patients and longer follow-up.
The September update will be the next opportunity to assess durability, safety and consistency. Success would strengthen the case that in vivo base editing can move beyond experimental mutation correction and become a practical one-time treatment for a chronic genetic disease affecting both the lungs and liver.
